Pharmacogenomics of “Core” Essential Medicines

M. Sello
{"title":"Pharmacogenomics of “Core” Essential Medicines","authors":"M. Sello","doi":"10.5772/intechopen.96581","DOIUrl":null,"url":null,"abstract":"Pharmacogenomics uses information about a person’s genetic makeup to choose the drugs dosage regimens that are likely to work best for that particular person. The genomic research has changed the “one size fits all” approach and opened the door to more personalized approaches that consider individual genetic makeup tend to enhance the efficacy and safety of drugs; thus saving time and money. Patient DNA influences multiple steps in which the drugs interact with the body and where will the drug act in the body. Genetic makeup-based prescription, design, and implementation of therapy do not only improve the outcome of treatments, but also reduce the risk of toxicity and other adverse events. The aim of the chapter is to explore the documented pharmacogenomics of essential as per pharmacogenomic biomarkers in drug labeling; and suggest efficacy and safety modifications. Polymorphism of drug metabolizing enzymes has the greatest effect on inter individual variability of drug response; affecting the response of individuals to drugs used in the treatment of diseases. Also, genetic deficiency of some enzymes limits effectiveness of drugs in treating concerned diseases. Gene testing prior to initiating concerned treatment is the best clinical practice that to enhance the efficacy and safety of drugs.","PeriodicalId":19917,"journal":{"name":"Pharmacogenetics","volume":"2 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenetics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5772/intechopen.96581","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Pharmacogenomics uses information about a person’s genetic makeup to choose the drugs dosage regimens that are likely to work best for that particular person. The genomic research has changed the “one size fits all” approach and opened the door to more personalized approaches that consider individual genetic makeup tend to enhance the efficacy and safety of drugs; thus saving time and money. Patient DNA influences multiple steps in which the drugs interact with the body and where will the drug act in the body. Genetic makeup-based prescription, design, and implementation of therapy do not only improve the outcome of treatments, but also reduce the risk of toxicity and other adverse events. The aim of the chapter is to explore the documented pharmacogenomics of essential as per pharmacogenomic biomarkers in drug labeling; and suggest efficacy and safety modifications. Polymorphism of drug metabolizing enzymes has the greatest effect on inter individual variability of drug response; affecting the response of individuals to drugs used in the treatment of diseases. Also, genetic deficiency of some enzymes limits effectiveness of drugs in treating concerned diseases. Gene testing prior to initiating concerned treatment is the best clinical practice that to enhance the efficacy and safety of drugs.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
“核心”基本药物药物基因组学
药物基因组学利用关于一个人的基因组成的信息来选择可能对这个特定的人最有效的药物剂量方案。基因组研究改变了“一刀切”的方法,为考虑个体基因组成的更个性化的方法打开了大门,这种方法往往会提高药物的有效性和安全性;从而节省时间和金钱。患者DNA影响药物与身体相互作用的多个步骤,以及药物在体内的作用位置。基于基因构成的治疗处方、设计和实施不仅可以改善治疗结果,还可以降低毒性和其他不良事件的风险。本章的目的是探讨药物标记中必要的药物基因组学记录,如药物基因组学生物标志物;并提出有效性和安全性的修改建议。药物代谢酶的多态性对药物反应的个体间变异影响最大;影响个体对用于治疗疾病的药物的反应的。此外,某些酶的遗传缺陷也限制了药物治疗相关疾病的有效性。在相关治疗开始前进行基因检测是提高药物疗效和安全性的最佳临床实践。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
In Silico Studies on Pharmacokinetics and Neuroprotective Potential of 25Mg2+: Releasing Nanocationites - Background and Perspectives Introductory Chapter: Pharmacogenetics Pharmacogenomics of “Core” Essential Medicines Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. The human serotonin receptor 2B: coding region polymorphisms and association with vulnerability to illegal drug abuse.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1